Tag: SOF-VAC mRNA vaccine enhancer
ASX biotech firm Noxopharm unveils anti-inflammatory skin disease drug
Australian biotech company Noxopharm Limited unveiled today its new preclinical product candidate from its Sofra technology platform that has shown effectiveness against inflammatory skin disease in preclinical models
Featured Article
A business-led approach to maximising your SAP investment
Manufacturers are responding to the low-growth environment by focusing on digitisation, ESG and portfolio reshaping, transforming into more digital, resilient, and sustainable organisations.
